1. Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE).

    Journal of Clinical Oncology 34(21):2516 (2016) PMID 27269942

    The AGO-OVAR 2.29/ENGOT-ov14/PENELOPE prospectively randomized phase III trial evaluated the addition of pertuzumab to chemotherapy in patients with platinum-resistant ovarian carcinoma with low tumor human epidermal growth factor receptor 3 (HER3) mRNA expression. We report the results of the p...
  2. The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.

    Tumor Biology 37(3):3009 (2016) PMID 26419591

    Patients with epithelial ovarian cancer (EOC) are at high risk of tumor recurrence. Human epididymis protein 4 (HE4) has been shown to be overexpressed in EOC. The primary aim of our study was to evaluate the role of HE4 in predicting recurrence in EOC patients. Furthermore, we assessed the role...
  3. High prevalence of BRCA1 stop mutation c.4183C>T in the Tyrolean population: implications for genetic testing.

    European Journal of Human Genetics 24(2):258 (2016) PMID 26014432 PMCID PMC4717197

    Screening for founder mutations in BRCA1 and BRCA2 has been discussed as a cost-effective testing strategy in certain populations. In this study, comprehensive BRCA1 and BRCA2 testing was performed in a routine diagnostic setting. The prevalence of the BRCA1 stop mutation c.4183C>T, p.(Gln1395Te...
  4. Evaluation of folate receptor 1 (FOLR1) mRNA expression, its specific promoter methylation and global DNA hypomethylation in type I and type II ovarian cancers.

    BMC Cancer 16(1):589 (2016) PMID 27485273 PMCID PMC4971744

    In this retrospective study we evaluated the respective correlations and clinical relevance of FOLR1 mRNA expression, FOLR1 promoter specific methylation and global DNA hypomethylation in type I and type II ovarian cancer. Two hundred fifty four ovarian cancers, 13 borderline tumours and 60 samp...
  5. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up.

    International Journal of Gynecological Cancer 26(1):2 (2016) PMID 26645990 PMCID PMC4679344

    The first joint European Society for Medical Oncology (ESMO), European SocieTy for Radiotherapy & Oncology (ESTRO) and European Society of Gynaecological Oncology (ESGO) consensus conference on endometrial cancer was held on 11-13 December 2014 in Milan, Italy, and comprised a multidisciplinary ...
  6. Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer.

    BMC Cancer 16(1):102 (2016) PMID 26879132 PMCID PMC4754861

    An increasing body of evidence shows that miR-34 family has tumor suppressive properties mediating apoptosis, cell cycle arrest and senescence. In ovarian cancer, miR34 family members were found to be under expressed. Particularly miR-34a has been revealed to be a direct transcriptional target o...
  7. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up.

    Radiotherapy and Oncology 117(3):559 (2015) PMID 26683800

    The first joint European Society for Medical Oncology (ESMO), European SocieTy for Radiotherapy & Oncology (ESTRO) and European Society of Gynaecological Oncology (ESGO) consensus conference on endometrial cancer was held on 11-13 December 2014 in Milan, Italy, and comprised a multidisciplinary ...
  8. Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statement.

    Wiener Medizinische Wochenschrift 165(19-20):387 (2015) PMID 26471371

    We reviewed the status of the use of the prophylactic long-acting granulocyte colony-stimulating factors (G-CSFs) pegfilgrastim and lipegfilgrastim in gynecologic malignancies. Long-acting G-CSFs should not be used in weekly regimens. Filgrastim is not indicated in patients with febrile and/or s...
  9. Dual-energy contrast-enhanced spectral mammography (CESM).

    Archives of Gynecology and Obstetrics 292(4):739 (2015) PMID 25814297

    Dual-energy contrast-enhanced mammography is one of the latest developments in breast care. Imaging with contrast agents in breast cancer was already known from previous magnetic resonance imaging and computed tomography studies. However, high costs, limited availability-or high radiation dose-l...
  10. European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Industry Partners--First Update 2015.

    International Journal of Gynecological Cancer 25(7):1328 (2015) PMID 26067859

    The first version of ENGOT's Requirements for Trials Between Academic Groups and Industry Partners in Europe was published 2010. This first update integrates the experiences made by the ENGOT network and the cooperative group studies while performing, analyzing, and publishing -among others - th...
  11. AGO Austria recommendations for genetic testing of patients with ovarian cancer.

    Wiener klinische Wochenschrift 127(15-16):652 (2015) PMID 26109557 PMCID PMC4536270

    In Austria, 700 women are diagnosed every year with ovarian carcinoma. Approximately 15% of the patients with epithelial ovarian cancer have a germline mutation in the BRCA1 or BRCA2 genes. The increased incidence of breast and/or ovarian cancer in genetically related family members has given ri...
  12. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.

    The Lancet 386(9992):433 (2015) PMID 26040499

    Adjuvant endocrine therapy compromises bone health in patients with breast cancer, causing osteopenia, osteoporosis, and fractures. Antiresorptive treatments such as bisphosphonates prevent and counteract these side-effects. In this trial, we aimed to investigate the effects of the anti-RANK lig...
  13. The European Network for Gynaecological Oncological Trial Groups Charta for Privileged Partnership.

    International Journal of Gynecological Cancer 25(6):1094 (2015) PMID 26098090

  14. Surgical and systemic management of endometrial cancer: an international survey.

    Archives of Gynecology and Obstetrics 291(4):897 (2015) PMID 25315381

    To ascertain the spectrum of clinical management of endometrial carcinoma (EC) the largest international survey was conducted to evaluate and identify differences worldwide. After validation of a 15-item questionnaire regarding surgical and adjuvant treatment of EC in Germany, an English-adapted...
  15. Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications.

    Cancer and Metastasis Reviews 34(1):41 (2015) PMID 25564455

    Folate can be transported into the cell by the reduced folate carrier (RFC), the proton-coupled folate transporter (PCFT), or the folate receptor (FR), of which various isoforms exist. While the RFC and PCFT are expressed by many normal cells, the FR is present only in a small proportion of norm...
  16. Carboplatin and nonpegylated liposomal doxorubicin in primary advanced or recurrent endometrial cancer: a phase 2 trial conducted by AGO Austria.

    International Journal of Gynecological Cancer 25(2):257 (2015) PMID 25611899

    Recurrent/advanced endometrial carcinoma carries a poor prognosis. Chemotherapy usually consists of cisplatin/doxorubicin and paclitaxel or the doublet of carboplatin and paclitaxel.We report on final results of the Austrian phase 2 AGO trial of nonpegylated doxorubicin citrate and carboplatin i...
  17. Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance.

    BMC Cancer 15:33 (2015) PMID 25655024 PMCID PMC4342867

    The purpose of this study was to evaluate serum HE4 as a biomarker to detect recurrent disease during follow-up of patients with endometrial adenocarcinoma (EAC). We performed a retrospective analysis of 98 EAC patients treated at Innsbruck Medical University, between 1999 and 2009. Twenty-six p...
  18. Incorporation of pazopanib in maintenance therapy of ovarian cancer.

    Journal of Clinical Oncology 32(30):3374 (2014) PMID 25225436

    Pazopanib is an oral, multikinase inhibitor of vascular endothelial growth factor receptor (VEGFR) -1/-2/-3, platelet-derived growth factor receptor (PDGFR) -α/-β, and c-Kit. Preclinical and clinical studies support VEGFR and PDGFR as targets for advanced ovarian cancer treatment. This study eva...
  19. Significant survival impact of MACC1 polymorphisms in HER2 positive breast cancer patients.

    European Journal of Cancer 50(12):2134 (2014) PMID 24910416

    Deregulation of hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (MET) signalling has been associated with poor clinical outcome in breast cancer and other cancers. The recently discovered metastasis-associated in colon cancer-1 (MACC1) gene is a key regulator of the HGF/M...
  20. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.

    The Lancet Oncology 15(8):799 (2014) PMID 24950985

    Angiogenesis is a valid target in the treatment of epithelial ovarian cancer. Trebananib inhibits the binding of angiopoietins 1 and 2 to the Tie2 receptor, and thereby inhibits angiogenesis. We aimed to assess whether the addition of trebananib to single-agent weekly paclitaxel in patients with...